77 results about "Ophthalmic disease" patented technology

The invention provides a myopia grading method driven by coupling of mechanical and morphological characteristics of corneal cells, and belongs to the technical field of myopia eye disease diagnosis and occurrence and development mechanisms based on artificial intelligence. The surface topography, Young modulus, adhesive power and other mechanical characteristics of corneal cells of patients with low, medium and high myopia are measured, corneal cell surface topography images obtained by an atomic force microscope are used as a cytoskeleton quantitative analysis data set, and edge extraction, brightness detection and multi-scale image segmentation methods are utilized to determine the surface topography of the corneal cells of the patients with low, medium and high myopia. The overall cytoskeleton distribution characteristics are quantified through the cytoskeleton region average complexity and cytoskeleton region average similarity, the method does not depend on dyeing, the tissue structure of the cytoskeleton can be evaluated more comprehensively, the method is suitable for more diversified cytoskeleton structures including complex clusters, a myopia grading model is established, and the myopia grading efficiency is improved. And a more direct cellular-level experimental basis is provided for the research on the occurrence and development mechanism of myopia.

The present invention provides a pharmaceutical composition for preventing or treating ophthalmic diseases, comprising a nuclear receptor subfamily 2 group F member 1 (NR2F1) inhibitor. The NR2F1 inhibitor of the present invention rejuvenates retinal cells by inhibiting the expression of the NR2F1 gene or the activity of the NR2F1 protein, and thus has the effects of reducing cellular senescence of retinal pigment epithelial cells and restoring visual function.

The group of inventions relates to optical elements with integrated electronic components and specifically to contact lenses with a built-in ultrathin digital camera, which are applicable for capturing video images, object recognition, implementing the user eye-tracking function, including, without limitation, while forming virtual, augmented, mixed or extended reality (VR / AR / MR / XR), as well as for diagnosing and compensating ophthalmic diseases, and for other applications. The contact lens housing (1) made of an optically transparent material contains a built-in electronic component containing a power source (2) and a camera (3) with at least one receiver (4) in the form of a matrix (8) of photosensitive elements. The camera (3) is equipped with an optical system implemented as at least one coding mask (5) separated from the receiver (4) by an intermediate layer (9) of homogeneous optically transparent material and disposed on the surface of or inside the lens housing (1). The invention makes it possible to significantly reduce the thickness of the contact lens containing an integrated camera and to produce an operational device that is comfortable for daily wearing.

The present invention provides a pharmaceutical composition for inhibiting the expression of the NFKBIZ gene and its application, belonging to the technical field of biomedicine. The present invention designs double-stranded nucleic acid molecules capable of targeting and regulating the expression of the NFKBIZ gene. By verifying the gene regulation efficiency of the nucleic acid molecules, multiple nucleic acid molecules are screened to be able to inhibit the expression of the NFKBIZ gene, and the purpose of efficiently inhibiting the expression of IκB-ζ protein is achieved at the protein level. At the same time, the present invention verifies the application of the pharmaceutical composition formed by coupling the above nucleic acid molecules and targeting ligand molecules in ophthalmic diseases. This pharmaceutical composition can solve the problems of low delivery efficiency and poor therapeutic effect of existing small molecule immunomodulatory drugs, endow small nucleic acid drugs with tissue-targeted delivery function, and has advantages such as long drug effect time and small side effects; in addition, the composition of the pharmaceutical composition is simple and easy to synthesize, and has good prospects for translational application.

The present invention relates to the technical field of pharmaceuticals, and in particular to a class of nitric oxide (NO) donor-containing compounds or pharmaceutically acceptable salts, a preparation method therefor, a pharmaceutical composition, and a use thereof in the treatment or prevention of an ocular hypertension-related ophthalmic disease and an optic nerve injury-related disease.

The present invention relates to the application of an EphA2-specific tyrosine kinase inhibitor, ALW-II-41-27, in ophthalmic diseases. The present invention has confirmed that at a specific concentration, ALW-II-41-27 can inhibit the expression of EphA2 in the retina, reduce the damage of acute high intraocular pressure to retinal tissue, and improve the survival rate of retinal ganglion cells, thereby playing a neuroprotective role, and thus being used for the preparation of treatments for preventing and treating acute high intraocular pressure or glaucoma.

Disclosed herein is a polysialic acid (PSA)-polymer conjugated compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein P is a poly (lactide-co-glycolide)-poly (ethylene glycol) copolymer (PLGA-PEG) and p is an integer from 4 to 200; nanoparticles comprising the same; and methods of treating ophthalmic diseases using the same. (I)

The application discloses a kind of laser treatment devices for ophthalmology, and it relates to the technical field of medical apparatus and instruments.The application includes eyeshade shell, massage column is slidably installed in eyeshade shell, camber surface drive ring is rotatably installed in eyeshade shell, sliding sheet is fixedly installed on massage column, hemispherical block is fixedly installed on sliding sheet, laser light source beam splitter is fixedly installed in eyeshade shell, a plurality of laser needle columns are fixedly installed at the output end of laser light source beam splitter, first light guide groove is provided in massage column, threaded groove is provided at the front end of eyeshade shell, liquid storage shell, liquid medicine atomization nozzle and liquid distribution shell are also fixedly installed in eyeshade shell, liquid inlet pipe is fixedly installed at the top end of liquid storage shell, liquid distribution pipe is fixedly installed and communicated on liquid distribution shell, atomization liquid pipe is fixedly installed and communicated on liquid medicine atomization nozzle, ultrasonic atomization sheet is fixedly installed in liquid medicine atomization nozzle, eye peripheral acupoints can be stimulated by laser acupuncture, the massage effect of massage column is combined, drug mist absorption is promoted, and the effect of treating ophthalmic diseases is achieved.

The present application relates to the technical field of medicine and provides a lanosterol derivative, a preparation method therefor and a use thereof. The structural formula of the lanosterol derivative provided by the present application is as shown in formula I or II. The lanosterol derivative provided by the present application has both lipid solubility and water solubility, and can effectively penetrate into the pathological site in the body, thereby improving the drug utilization rate. The results of embodiments show that the lanosterol derivative provided by the present application has a significantly higher solubility in water than lanosterol or 25-hydroxylanosterol and shows a significant therapeutic effect on a cataract in animal in vivo experiments. Therefore, the derivative has wide prospects in the preparation of drugs for treating eye diseases or conditions.

The present invention provides an ophthalmic composition comprising an active pharmaceutically compound non-covalently bound to albumin. The composition of the present invention is useful for treatment of ophthalmic diseases and disorders.

This invention discloses an AI-based automatic analysis color diagnosis system for fundus lesions, relating to the field of ophthalmic disease diagnosis technology. It includes a fundus image acquisition module and an AI color analysis module. This AI-based automatic analysis color diagnosis system for fundus lesions, through its fundus image acquisition module, AI color analysis module, and analysis model construction module, inputs acquired fundus color images into a fundus color image processing and analysis model to obtain fundus color feature data. It then identifies the patient's lesions, diagnoses the patient's ophthalmic disease based on the identified lesions, and determines the location of the lesions in the fundus images using the fundus color feature data. This constructs a fundus image color evaluation system, improving the accuracy and reliability of ophthalmic diagnosis and assisting in the diagnosis and treatment of fundus diseases.

The application discloses an ophthalmic disease visual video generation method and device, a terminal equipment and a storage medium, which comprises the following steps: inputting an initial visual description text describing the vision of a patient into a preset language large model, so that the language large model combines a preset eye disease visual symptom knowledge graph to perform semantic analysis on the initial visual description text, and according to the semantic analysis result, the initial visual description text is optimized to generate a visual description text recording a dynamic visual scene of the patient; and inputting the visual description text into a preset text-to-video model, so that the text-to-video model outputs a subjective visual video consistent with the visual scene of the patient according to the visual description text. Therefore, the application can output a subjective visual video consistent with the visual scene of the patient, thereby effectively helping doctors understand the visual symptoms of the patient and improving the diagnosis efficiency of the doctors.

Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.

The invention relates generally to the fields of biology and health sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in amniotic membrane tissue and umbilical cord tissue preparations.

The invention relates to a medical image super-resolution processing method and system, electronic equipment and a medium, and the method comprises the steps: carrying out the hybrid degradation operation and data enhancement operation of a medical image to be subjected to super-resolution processing, and obtaining a to-be-processed image; the to-be-processed image is input to an improved generative adversarial network to obtain a super-resolution image, the improved generative adversarial network is constructed by a preset generator, a preset discriminator and a mixed loss function module, and the preset generator is constructed by a residual dense block, a multi-scale attention module and an up-sampling module; the up-sampling module is constructed by two-stage sub-pixel convolution, and the mixed loss function module is used for optimizing the loss of the super-resolution image. Therefore, the problems that when an existing super-resolution technology is applied to medical images, the low-quality fundus image reconstruction capacity is insufficient, blurring or artifacts are likely to be generated, and missed diagnosis or misdiagnosis is likely to be caused are solved, high-fidelity and low-artifact fundus image reconstruction is achieved, and diagnosis of ophthalmic diseases is assisted.

The invention relates generally to the fields of biology and health sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in amniotic membrane tissue and umbilical cord tissue preparations.

Therapeutic methods and ophthalmic compositions for reducing ocular mast cell degranulation and / or ocular mast cell cytokine production in a human subject, inhibiting ocular mast cell activation in a human subject, treating dry eye disease (DED) or allergic conjunctivitis (AC) in a human subject, inhibiting mast cell activation in a human subject, and reducing or alleviating a sign or symptom of dry eye disease in a human subject using a BTK inhibitor are described. The disclosure also includes therapeutic methods and ophthalmic compositions for reducing or alleviating a sign or symptom of allergic conjunctivitis in a human subject and treating allergic conjunctivitis in a human subject using a BTK inhibitor.

Disclosed herein are drug delivery compositions to treat ophthalmic diseases.

Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.

The present invention is directed to methods of treating nasal and / or ophthalmic diseases, symptoms, or disorders that are therapeutically responsive to corticosteroid therapy by delivering aqueous solution formulations comprising a corticosteroid to nasal and ophthalmic tissues. The invention is also directed to methods, systems, devices, and compositions for delivering aqueous solution formulations comprising a corticosteroid and an antihistamine to nasal and ophthalmic tissues.

Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.

The present invention provides a pharmaceutical composition for preventing or treating ophthalmic diseases, the pharmaceutical composition comprising an expression vector including: a polynucleotide encoding early growth response 1 (EGR1); and a promoter operably linked thereto.

An ophthalmic pharmaceutical composition comprising or consisting of 1 part by weight of an active pharmaceutical ingredient, 0.95 to 1.25 parts by weight of a liquid substrate, and 0.35 to 0.45 parts by weight of a solid substrate, wherein the particle size of the active pharmaceutical ingredient is D 90 An ophthalmic pharmaceutical composition satisfying ≤50 μm, a method for preparing the same, an ophthalmic kit containing the ophthalmic pharmaceutical composition, and the use of the ophthalmic pharmaceutical composition or ophthalmic kit in the preparation of a pharmaceutical for the prevention and / or treatment of an ophthalmic disease.

An eye drop composition for the prevention or treatment of ophthalmic diseases is provided, including: (a) a lyophilized preparation including atropine or a pharmaceutically acceptable salt thereof; and (b) a reconstituting diluent, the lyophilized preparation being separate from the reconstituting diluent. A method for preparing the eye drop composition is also provided, which includes steps of: (a) contacting a buffer salt system in the lyophilized preparation with the atropine or the pharmaceutically acceptable salt thereof, and optionally, one or more of a matrix agent and a stabilizer, and lyophilizing to obtain the lyophilized preparation; and (b) contacting a buffer salt system in the reconstitution diluent optionally with one or more of an osmotic pressure regulator, a chelating agent, and a bacteriostatic agent to obtain the reconstitution diluent.

The present disclosure relates to a composition including non-autologous plasma or serum and a polymer; method of treating ophthalmic diseases (e.g., dry eye syndrome) or moisturizing and / or repairing non-keratinized surfaces including non-healing wounds with a composition including non-autologous plasma or serum and a polymer; and a therapeutic agent delivery device for delivery of the composition to the eye or a non-keratinized surface of a subject.

An ultrasound-excited elastography device and detection method for measuring the mechanical properties of the cornea and retina are disclosed. The ultrasound excitation module uses three-dimensionally localizable focused ultrasound waves to excite elastic waves in the cornea or retina. Its transducer axis is angled to the OCT optical axis, and the sound wave path is deflected by an obliquely placed acoustic reflector. The OCT module dynamically captures the spatiotemporal displacement signals of the tissue induced by the elastic waves through a dual-scan mode, achieving high-resolution imaging of the anterior segment and fundus. The eye cup fitting module, combined with a biocompatible structure, adapts to the eye contour and coordinates the incident angle of the sound waves to optimize the acoustic-optical coupling efficiency. The data processing module derives the Young's modulus distribution of the tissue using an elastography algorithm. The detection method achieves high-precision quantitative analysis of the mechanical properties of the cornea and retina through non-invasive ultrasound-OCT co-excitation and signal acquisition, combined with a motion platform to compensate for eye movement deviations in real time. This invention provides a reliable tool for assisting in the diagnosis of ophthalmic diseases.

The invention discloses a visual video generation method and device for ophthalmic diseases, terminal equipment and a storage medium, and the method comprises the steps: inputting an initial visual description text for describing the vision of a patient into a preset large language model, so as to enable the large language model to be combined with a preset visual symptom knowledge graph of the ophthalmic diseases, performing semantic analysis on the initial visual description text, optimizing the initial visual description text according to a semantic analysis result, and generating a visual description text recording a dynamic visual scene of the patient; and inputting the visual description text into a preset text video model, so that the text video model outputs a subjective visual video meeting the view of the patient according to the visual description text. Therefore, the method and the device can output the subjective visual video meeting the view of the patient, thereby effectively helping a doctor to know the visual symptom of the patient, and improving the diagnosis efficiency of the doctor.

The invention discloses an interpretable single-domain generalization method and system for multi-label classification of ophthalmic diseases, and the method comprises the following steps: obtaining the feature representation of an original image sample and an enhanced image sample through double-branch input processing; a feature guiding mechanism is applied, and an interpretable signal is utilized to carry out weighted guiding on features so as to focus a clinical related area; domain invariant features are extracted, masks are generated through similarity calculation, domain sensitive features are filtered out, and feature representation insensitive to distribution changes is reserved; modeling relevance among disease tags, learning relevance among tag vectors through an attention mechanism, and calculating the existence probability of each tag in the image; attention feature alignment is executed, and attention vector consistency of different branches is restrained. Through collaborative design of double-branch feature processing, a feature guide mechanism, domain invariant feature filtering and label association modeling, a multi-label classification system which can be generalized to an unknown domain only through single-source domain training is realized.